BridgeBio Pharma BBIO 深 滬
等待開盤 09-18 09:30:00 美东时间
67.31
-0.990
-1.45%
華盛通- 最 高69.99
- 今 開69.72
- 成交量 234.41万股
- 最 低 66.93
- 昨 收 68.30
- 總市值 131.59亿
- 52周最高 93.415
- 市盈率 靜 --
- 換手率 1.20%
- 52周最低 50.50
- 委 比 93.66%
- 總股本 1.95亿
- 歷史最高 93.415
- 量 比 0.76
- 振 幅 4.48%
- 歷史最低 4.98
- 每 手 1
- 風險率 8.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
BridgeBio Pharma Inc. (NASDAQ:BBIO)on Wednesday shared fresh clinical updates on infigratinib. The company’s 52-week treatment with oral infigratinib in the PROPEL 3 study showed favorable trends versus placebo across exploratory endpoints that go beyond growth, including sleep apnea and otitis medi...
09-09 22:33
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
09-09 20:21
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (D...
09-09 04:08
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BridgeBio Oncology Therapeutics announced new clinical data for its KRAS<sup>G12C</sup> inhibitor BBO-8520, showing a 75% objective response rate (ORR) when combined with pembrolizumab in second-line NSCLC patients previously treated with KRAS<sup>G12C</sup> inhibitors. BBO-8520 monotherapy achieved a 63% ORR and 100% disease control rate in untreated NSCLC patients. The company is prioritizing BBO-8520 in combination with checkpoint inhibitors a...
09-08 20:05
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
09-01 23:20
BBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (BBOT) announced that its leadership team will participate in three upcoming investor conferences: Cantor Global Healthcare Conference 2026 on September 9, Citi's 2026 Biopharma Back to School Conference on September 10, and Morgan Stanley's 24th Annual Global Healthcare Conference on September 15. Live webcasts and 90-day replays will be available on the company's website. BBOT focuses on developing novel small mo...
09-01 20:05
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
U.S. President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cut healthcare costs for American consu...
09-01 12:10
白宫再与9家药企达成降价协议
美国白宫当地时间8月31日发布声明称，美国总统特朗普宣布与九家制药商达成新协议，以降低在美处方药价格，使其与最惠国价格（MFN）保持一致。 由此，签署MFN协议...
09-01 08:32
